We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+13.47%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.57B
AUM Growth
+$553M
(+18%)
Cap. Flow
+$561M
Cap. Flow
% of AUM
15.73%
Top 10 Holdings %
Top 10 Hldgs %
49.57%
Holding
170
New
38
Increased
32
Reduced
29
Closed
33
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$104M |
| 2 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$79.7M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$55.2M |
| 4 |
YARW
Yarrow Bioscience
YARW
|
+$54M |
| 5 |
FOLD
Amicus Therapeutics
FOLD
|
+$32.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AnaptysBio
ANAB
|
+$58.5M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$32.9M |
| 3 |
Intuitive Surgical
ISRG
|
+$25.4M |
| 4 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$24.2M |
| 5 |
Zimmer Biomet
ZBH
|
+$24.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.46% |
| 2 | Consumer Staples | 0.67% |
| 3 | Consumer Discretionary | 0.06% |
| 4 | Industrials | 0.02% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VBIV
26
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $33.8M | 0.95% |
322,195
| – | – |
|
|
CBAY
27
DELISTED
Cymabay Therapeutics
CBAY
| $33.7M | 0.95% |
2,802,821
+116,939
| +4% | +$1.45M |
|
28
uniQure
QURE
$3.54B
| $32.8M | 0.92% |
1,394,628
+346,678
| +33% | +$7.56M |
|
29
Puma Biotechnology
PBYI
$481M
| $30.1M | 0.84% |
442,179
-261,641
| -37% | -$19.6M |
|
|
QTNT
30
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $28.4M | 0.8% |
150,826
| – | – |
|
31
iRhythm Holdings
IRTC
$4.06B
| $26.4M | 0.74% |
419,706
-7,665
| -2% | -$475K |
|
32
Regenxbio
RGNX
$588M
| $26.3M | 0.74% |
881,106
-540,080
| -38% | -$15.7M |
|
33
Vertex Pharmaceuticals
VRTX
$140B
| $24.8M | 0.69% |
151,898
+13,272
| +10% | +$2.17M |
|
|
34
AnaptysBio
ANAB
$1.73B
| $24.7M | 0.69% |
237,281
-519,106
| -69% | -$58.5M |
|
|
NEPT
35
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
| $24.1M | 0.67% |
6,124
+143
| +2% | +$593K |
|
36
Akebia Therapeutics
AKBA
$266M
| $23.5M | 0.66% |
2,462,400
+475,000
| +24% | +$6.64M |
|
37
Assembly Biosciences
ASMB
$719M
| $23.4M | 0.66% |
39,719
-5,000
| -11% | -$3.1M |
|
38
Aldeyra Therapeutics
ALDX
$93.5M
| $23.1M | 0.65% |
3,085,458
| – | – |
|
|
BOLD
39
DELISTED
Audentes Therapeutics, Inc
BOLD
| $22.7M | 0.64% |
756,215
-25,094
| -3% | -$850K |
|
|
KDMN
40
DELISTED
Kadmon Holdings, Inc.
KDMN
| $22M | 0.61% |
5,165,746
-20,101
| -0.4% | -$86K |
|
41
Teladoc Health
TDOC
$1.12B
| $21M | 0.59% |
+520,000
| New | +$19.6M |
|
|
LKFT
42
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.94B
| $20.6M | 0.58% |
206,305
| – | – |
|
43
Agios Pharmaceuticals
AGIO
$2.02B
| $20.4M | 0.57% |
+250,000
| New | +$19.3M |
|
|
ABLX
44
DELISTED
Ablynx NV
ABLX
| $20.2M | 0.57% |
370,000
+120,000
| +48% | +$5.95M |
|
|
ECYT
45
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $20M | 0.56% |
2,201,700
+750,000
| +52% | +$4.14M |
|
|
RVNC
46
DELISTED
Revance Therapeutics, Inc.
RVNC
| $19.1M | 0.53% |
618,957
+218,957
| +55% | +$7.04M |
|
47
Wave Life Sciences
WVE
$1.03B
| $18.6M | 0.52% |
462,798
-200,000
| -30% | -$8.41M |
|
48
ADMA Biologics
ADMA
$2.18B
| $17.6M | 0.49% |
3,821,102
| – | – |
|
49
Madrigal Pharmaceuticals
MDGL
$11.8B
| $16.6M | 0.47% |
142,522
-46,371
| -25% | -$5.72M |
|
50
Humana
HUM
$46.8B
| $16.3M | 0.46% |
60,718
-16,782
| -22% | -$4.54M |
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
LSERS
CAG
MCM
Perceptive Advisors's Q1 2018 Portfolio in Review
As of Q1 2018, Perceptive Advisors held 170 positions worth $3.57B, up 18% from $3.02B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Perceptive Advisors deployed $561M of net new capital in Q1 2018, opening 38 new positions and adding to 32 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 873,450 shares worth $97.4M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
On the sell side, the largest reduction was AnaptysBio, an estimated $58.5M trimmed.
- Perceptive Advisors's largest Q1 2018 buy was Alexion Pharmaceuticals: 873,450 shares worth $97.4M.
- Perceptive Advisors added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018, an estimated $79.7M increase.
- Perceptive Advisors's biggest Q1 2018 reduction was AnaptysBio, cutting an estimated $58.5M.
- Perceptive Advisors fully exited Zimmer Biomet in Q1 2018, selling an estimated $24.1M.
- Perceptive Advisors's ten largest holdings make up 50% of its $3.57B portfolio in Q1 2018.
- Perceptive Advisors opened 38 new positions and closed 33 in Q1 2018.
- Perceptive Advisors's portfolio value rose 18% quarter-over-quarter to $3.57B.
Based on Perceptive Advisors's 13F filing for Q1 2018, filed 15 May 2018.